^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EMB-02

    i
    Other names: EMB-02
    Associations

    News

    Trials
    Company:
    EpimAb Biotherap
    Drug class:
    PD1 inhibitor, LAG-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    9ms
    Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors (ESMO 2023)
    Conclusions EMB-02 has demonstrated a tolerable safety profile and encouraging anti-tumor activity during the dose escalation phase, warranting further development. Expansion cohorts in select advanced solid tumours are ongoing.
    Clinical • P1 data • Metastases
    |
    LAG3 (Lymphocyte Activating 3)
    |
    LAG3 expression
    |
    EMB-02